187 related articles for article (PubMed ID: 27193167)
1. Oxygen consumption deficit in Huntington disease mouse brain under metabolic stress.
Lou S; Lepak VC; Eberly LE; Roth B; Cui W; Zhu XH; Öz G; Dubinsky JM
Hum Mol Genet; 2016 Jul; 25(13):2813-2826. PubMed ID: 27193167
[TBL] [Abstract][Full Text] [Related]
2. Oxidative metabolism and Ca2+ handling in isolated brain mitochondria and striatal neurons from R6/2 mice, a model of Huntington's disease.
Hamilton J; Pellman JJ; Brustovetsky T; Harris RA; Brustovetsky N
Hum Mol Genet; 2016 Jul; 25(13):2762-2775. PubMed ID: 27131346
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial Respiration Changes in R6/2 Huntington's Disease Model Mice during Aging in a Brain Region Specific Manner.
Burtscher J; Di Pardo A; Maglione V; Schwarzer C; Squitieri F
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751413
[TBL] [Abstract][Full Text] [Related]
4. Increased glutathione levels in cortical and striatal mitochondria of the R6/2 Huntington's disease mouse model.
Choo YS; Mao Z; Johnson GV; Lesort M
Neurosci Lett; 2005 Sep; 386(1):63-8. PubMed ID: 15993538
[TBL] [Abstract][Full Text] [Related]
5. Oxidative metabolism in YAC128 mouse model of Huntington's disease.
Hamilton J; Pellman JJ; Brustovetsky T; Harris RA; Brustovetsky N
Hum Mol Genet; 2015 Sep; 24(17):4862-78. PubMed ID: 26041817
[TBL] [Abstract][Full Text] [Related]
6. N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington's disease.
Wright DJ; Renoir T; Smith ZM; Frazier AE; Francis PS; Thorburn DR; McGee SL; Hannan AJ; Gray LJ
Transl Psychiatry; 2015 Jan; 5(1):e492. PubMed ID: 25562842
[TBL] [Abstract][Full Text] [Related]
7. Exercise training normalizes mitochondrial respiratory capacity within the striatum of the R6/1 model of Huntington's disease.
Herbst EA; Holloway GP
Neuroscience; 2015 Sep; 303():515-23. PubMed ID: 26186895
[TBL] [Abstract][Full Text] [Related]
8. Selective striatal mtDNA depletion in end-stage Huntington's disease R6/2 mice.
Hering T; Birth N; Taanman JW; Orth M
Exp Neurol; 2015 Apr; 266():22-9. PubMed ID: 25682918
[TBL] [Abstract][Full Text] [Related]
9. Progressive Mitochondrial Dysfunction of Striatal Synapses in R6/2 Mouse Model of Huntington's Disease.
Petersen MH; Willert CW; Andersen JV; Madsen M; Waagepetersen HS; Skotte NH; Nørremølle A
J Huntingtons Dis; 2022; 11(2):121-140. PubMed ID: 35311711
[TBL] [Abstract][Full Text] [Related]
10. Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington's Disease.
Valdeolivas S; Sagredo O; Delgado M; Pozo MA; Fernández-Ruiz J
Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28333097
[TBL] [Abstract][Full Text] [Related]
11. Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice.
Ooms M; Rietjens R; Rangarajan JR; Vunckx K; Valdeolivas S; Maes F; Himmelreich U; Fernandez-Ruiz J; Bormans G; Van Laere K; Casteels C
Neurobiol Aging; 2014 Dec; 35(12):2858-2869. PubMed ID: 25018107
[TBL] [Abstract][Full Text] [Related]
12. Brain Cholesterol Synthesis and Metabolism is Progressively Disturbed in the R6/1 Mouse Model of Huntington's Disease: A Targeted GC-MS/MS Sterol Analysis.
Kreilaus F; Spiro AS; Hannan AJ; Garner B; Jenner AM
J Huntingtons Dis; 2015; 4(4):305-18. PubMed ID: 26639223
[TBL] [Abstract][Full Text] [Related]
13. Neurochemical changes in Huntington R6/2 mouse striatum detected by in vivo 1H NMR spectroscopy.
Tkac I; Dubinsky JM; Keene CD; Gruetter R; Low WC
J Neurochem; 2007 Mar; 100(5):1397-406. PubMed ID: 17217418
[TBL] [Abstract][Full Text] [Related]
14. Localized changes to glycogen synthase kinase-3 and collapsin response mediator protein-2 in the Huntington's disease affected brain.
Lim NK; Hung LW; Pang TY; Mclean CA; Liddell JR; Hilton JB; Li QX; White AR; Hannan AJ; Crouch PJ
Hum Mol Genet; 2014 Aug; 23(15):4051-63. PubMed ID: 24634145
[TBL] [Abstract][Full Text] [Related]
15. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
[TBL] [Abstract][Full Text] [Related]
16. Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington's disease.
Samadi P; Boutet A; Rymar VV; Rawal K; Maheux J; Kvann JC; Tomaszewski M; Beaubien F; Cloutier JF; Levesque D; Sadikot AF
Genes Brain Behav; 2013 Feb; 12(1):108-24. PubMed ID: 23006318
[TBL] [Abstract][Full Text] [Related]
17. Increased calbindin-D28k immunoreactivity in striatal projection neurons of R6/2 Huntington's disease transgenic mice.
Sun Z; Wang HB; Deng YP; Lei WL; Xie JP; Meade CA; Del Mar N; Goldowitz D; Reiner A
Neurobiol Dis; 2005 Dec; 20(3):907-17. PubMed ID: 15990326
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial dysfunction in chromaffin cells from the R6/1 mouse model of Huntington's disease: Impact on exocytosis and calcium current regulation.
Fernández A; Martínez-Ramírez C; Gómez A; de Diego AMG; Gandía L; Casarejos MJ; García AG
Neurobiol Dis; 2023 Apr; 179():106046. PubMed ID: 36806818
[TBL] [Abstract][Full Text] [Related]
19. Sustained striatal ciliary neurotrophic factor expression negatively affects behavior and gene expression in normal and R6/1 mice.
Denovan-Wright EM; Attis M; Rodriguez-Lebron E; Mandel RJ
J Neurosci Res; 2008 Jun; 86(8):1748-57. PubMed ID: 18293418
[TBL] [Abstract][Full Text] [Related]
20. Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease.
Bisogno T; Martire A; Petrosino S; Popoli P; Di Marzo V
Neurochem Int; 2008 Jan; 52(1-2):307-13. PubMed ID: 17664017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]